IGHE and autoimmune thyroid disease: In conclusion, thyroid autoimmunity alone does not seem of particular help in the stratification of CSU patients, and baseline total IgE levels currently remain the only and most easily available prognostic marker for omalizumab response in patients with severe CSU.